On International Women's Day, which is celebrated every year on 8 March, we celebrate the significant progress in women's healthcare, which has also been made possible by our commitment to innovation in the area of market access strategies.

Within our network, a particular company exemplifies dedication to advancing women's health. With its minimally invasive approach and uterine-preserving benefits, this treatment offers an exciting new option to women affected by uterine fibroids.

Uterine fibroids are a prevalent condition, affecting millions of women worldwide. With an incidence of 25-30%, fibroids are one of the most common benign diseases of the uterus. Accompanying symptoms and signs include heavy menstrual bleeding, anemia due to iron deficiency in the most extreme cases, and other symptoms, potentially impairing pregnancy. With myomas diagnosed in 41.6% of women globally and 40.5% in Germany alone, these advancements greatly improve the quality of life for affected women.

Bringing innovative treatment methods to the market requires a sound strategy to demonstrate the clinical imperative and economic viability to the governing authorities. We have collaborated with this company in developing and executing a market access strategy in Germany that has supported improved facility funding in the hospital setting and continues to pursue the full recognition of innovative potential within the German healthcare landscape.

At inspiring-health, our journey doesn't end with approvals; it extends to ensuring tangible benefits for patients. Through selective contracting with insurance providers, we bridge the gap between advancements in care and accessibility, ensuring that women who need it most can benefit from these transformative solutions.

By fostering collaboration and executing on strategies that meet the clinical and economic evidentiary requirements to efficiently access new markets, we can ensure that every woman has access to important innovative treatments.